Amblyopia is a visual developmental disease in which one eye's vision does not correctly develop during early life. The optical parts of the brain, not the eye itself, are where there is a weakness.
A misaligned eye or an out-of-focus eye may be the cause of the disturbance to early visual development. The vision loss remains even after surgical alignment or focuses correction.
Amblyopia (lazy eye) affects 3% of the world's population and is the leading cause of vision loss in children.
The most common lazy eye treatment is patching the dominant eye. However, it has many drawbacks, including low compliance, high recurrence, being primarily monocular, and being stigmatized in society.
For this reason, NovaSight has developed CureSight for amblyopia treatment, designed to replace traditional eye patching.
So continue reading to learn more!
What is the New Treatment for Amblyopia?
On 24th October 2022 FDA approved CureSight as the latest advancement to treat amblyopia in children.
CureSight is a device that teaches the visual system to use both eyes simultaneously. The user wears red-blue therapy glasses to view any streaming video content.
CureSight blurs the center of vision of the image displayed to the strong eye by utilizing real-time image processing, various algorithms, and eye-tracking technologies.
This allows the brain to fill in the fine details of the amblyopic eye's vision and teaches the two eyes to function together.
CureSight is designed to be used at home. It shares treatment reports with physicians via a cloud portal.
The CureSight cloud portal allows ECPs to monitor patient treatment results and other developments.
Also, a nationwide monitoring center provides complete, beginning-to-end physician and patient support.
Before considering any treatment, you must know whether it is effective.
We have discussed the results and efficacy of this new treatment for amblyopia below.
So please read them carefully!
How effective is this new treatment for amblyopia?
NovaSight conducted clinical trials in 103 children, ages 4 to 9, for 16 weeks. The following are the findings of the trial:
References:
https://www.news-medical.net/health/New-hope-for-adults-with-amblyopia.aspx
https://www.medicaldevice-network.com/news/novasight-positive-data-amblyopia-treatment-device/
